uniQure to Participate in Multiple Upcoming Industry Conferences in December

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced its participation in several upcoming virtual investor and scientific conferences. Key events include a fireside chat on December 2, 2020, at the Evercore ISI HealthCONx Conference, featuring R&D president Ricardo Dolmetsch. At the American Society of Hematology Annual Meeting, clinical data on etranacogene dezaparvovec in hemophilia B will be presented on December 8, 2020, followed by an investor webcast. Other conferences include the Gene Therapy Conference for Neurological Disorders and the Lega Italiana Ricerca Huntington Annual Conference, with presentations focused on gene therapies.

LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences:

• Evercore ISI 3^rd Annual HealthCONx Conference, December 1 - 3, 2020

• A fireside chat with Ricardo Dolmetsch, Ph.D., president of research & development, will take place today, December 2, 2020 from 8:25 – 8:45 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.
  
  
• Members of uniQure’s management team including Matt Kapusta, chief executive officer, Ricardo Dolmetsch, Ph.D., president of research & development, and Maria Cantor, chief communications officer, with Chiara Russo, associate director of investor relations and communications, also will participate in virtual one-on-one investor meetings throughout the day.
  

• American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2020

• Dr. Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trail of etranacogene dezaparvovec in hemophilia B as part of the ASH Late-Breaking Oral Presentations on Tuesday, December 8, 2020 at 11:45 a.m. ET.
  
  
• Following the late-breaking oral presentation, uniQure management and Dr. Pipe will host an investor webcast at 5:00 p.m. ET to review the pivotal top-line HOPE-B data presented at ASH. The live webcast along with slides can be accessed through the link displayed in the Investor section of the uniQure website. The webcast will be archived for 90 days.
  

• 2nd Annual Gene Therapy Conference for Neurological Disorders, December 8-10, 2020

• Lisa Spronck, ERT, a scientist in non-clinical development, will present “First-in-Human AAV Gene Therapy for Huntington’s Disease from Pre-Clinical to the Clinic” on Thursday, December 10 at 8:55 a.m. ET.

• Lega Italiana Ricerca Huntington Annual Conference, December 12, 2020

• David Cooper, M.D., vice president of clinical research CNS, will present “Updates on HD-GeneTRX-1: A Phase 1/2 Clinical Trial of CNS-administered Gene Therapy (AMT-130) for Early-Stage HD” on Saturday, December 12 at 11:40 a.m. CET.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:				FOR MEDIA:
Maria E. Cantor		Chiara Russo		Tom Malone
Direct: 339-970-7536		Direct: 617-306-9137		Direct:  339-970-7558
m.cantor@uniQure.com		c.russo@uniQure.com		t.malone@uniQure.com

FAQ

What conferences is uniQure participating in December 2020?

uniQure is participating in the Evercore ISI HealthCONx Conference, the American Society of Hematology Annual Meeting, the 2nd Annual Gene Therapy Conference for Neurological Disorders, and the Lega Italiana Ricerca Huntington Annual Conference.

Who will present at the ASH Annual Meeting for uniQure?

Dr. Steven Pipe will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B on December 8, 2020.

When is the investor webcast for the HOPE-B data?

The investor webcast to review the HOPE-B data will take place on December 8, 2020, at 5:00 p.m. ET.

What is the focus of the presentation at the Gene Therapy Conference?

Lisa Spronck will present on 'First-in-Human AAV Gene Therapy for Huntington’s Disease from Pre-Clinical to the Clinic' on December 10, 2020.

Who will present clinical trial updates at the Lega Italiana Ricerca Huntington Annual Conference?

David Cooper will present updates on HD-GeneTRX-1, a Phase 1/2 clinical trial for gene therapy AMT-130, on December 12, 2020.